期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Enhanced Mn^(2+)solidification and NH_(4)^(+)-N removal from electrolytic manganese metal residue via surfactants
1
作者 Jiancheng Shu Xiangfei Zeng +4 位作者 danyang sun Yong Yang Zuohua Liu Mengjun Chen Daoyong Tan 《Chinese Journal of Chemical Engineering》 SCIE EI CAS CSCD 2022年第9期205-212,共8页
Electrolytic manganese metal residue(EMMR)harmless treatment has always lacked a low-cost and quick processing technology.In this study,surfactants,namely tetradecyl trimethylammonium chloride(TTC),sodium dodecyl benz... Electrolytic manganese metal residue(EMMR)harmless treatment has always lacked a low-cost and quick processing technology.In this study,surfactants,namely tetradecyl trimethylammonium chloride(TTC),sodium dodecyl benzene sulfonate(SDBS),sodium lignin sulfonate(SLS),and octadecyl trimethylammonium chloride(OTC),were used in the solidification of Mn^(2+)and removal of NH_(4)^(+)-N from EMMR.The Mn^(2+)and NH_(4)^(+)-N concentrations under different reaction conditions,Mn^(2+)solidification and NH_(4)^(+)-N removal mechanisms,and leaching behavior were studied.The results revealed that the surfactants could enhance the Mn^(2+)solidification and NH_(4)^(+)-N removal from EMMR,and the order of enhancement was as follows:TTC>SDBS>OTC>SLS.The NH_(4)^(+)-N and Mn^(2+)concentrations were 12.3 and 0.05 mg·L^(-1)with the use of 60.0 mg·kg^(-1)TTC under optimum conditions(solid–liquid ratio of 1.5:1,EMMR to BRM mass ratio of 100:8,temperature of 20℃,and reaction duration of 12 h),which met the integrated wastewater discharge standard(GB8978-1996).Mn^(2+)was mainly solidified as Mn(OH)_(2),MnOOH and MnSiO_(3),and NH_(4)^(+)-N in EMMR was mostly removed in the form of ammonia.The results of this study could provide a new idea for cost-effective EMMR harmless treatment. 展开更多
关键词 Electrolytic manganese metal residue Mn^(2+)solidification NH_(4)^(+)-N removal SURFACTANTS
下载PDF
年龄及甲状腺球蛋白抗体阳性水平对分化型甲状腺癌预后的影响 被引量:8
2
作者 孙丹阳 孟召伟 +6 位作者 谭建 李宁 贾强 王任飞 钱玉梅 何雅静 郑薇 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2021年第12期1068-1074,共7页
目的在不同年龄段甲状腺球蛋白抗体(TgAb)阳性的分化型甲状腺癌(differentiated thyroid cancer,DTC)患者中,探讨经手术及131I治疗后的预后影响因素及TgAb水平及变化趋势等在DTC患者预后及随访中的价值。方法回顾性分析131例TgAb阳性的... 目的在不同年龄段甲状腺球蛋白抗体(TgAb)阳性的分化型甲状腺癌(differentiated thyroid cancer,DTC)患者中,探讨经手术及131I治疗后的预后影响因素及TgAb水平及变化趋势等在DTC患者预后及随访中的价值。方法回顾性分析131例TgAb阳性的DTC患者临床资料,按照年龄分为年轻组(年龄<55岁,95例)与年长组(年龄≥55岁,36例),根据疗效评价分为疗效满意组(110例)和疗效不满意组(21例),采用χ2检验、t检验等比较不同组别间临床病理特征。通过logistic回归分析影响患者预后的独立危险因素。通过受试者工作特征曲线确定诊断DTC患者持续或复发的TgAb界值,以Kaplan-Meier回归曲线分析TgAb转阴时间。P<0.05为差异有统计学意义。结果在年轻组患者中,131I治疗前血清TgAb水平高及肿瘤合并颈侧区淋巴结转移是患者预后差的独立影响因素[OR=0.89(95%CI 0.83~0.95),OR=0.15(95%CI 0.05~0.52);均P<0.05],而年长组患者肿瘤腺外侵犯以及131I治疗前血清TgAb越高则患者预后越差[OR=0.05(95%CI 0~0.83),OR=0.91(95%CI 0.76~1.13);P<0.05]。预测DTC持续或复发的血清TgAb界值为315.5 IU/mL(年轻组为246.0 IU/mL,年长组为516.5 IU/mL)。所有患者血清TgAb平均转阴时间为(26.37±2.22)个月[年轻组为(23.28±2.37)个月,年长组为(32.64±4.07)个月],首次131I治疗后1年TgAb下降率>50%的患者发生疾病持续或复发的概率均低于未下降组(P<0.05)。结论在年轻组患者中131I治疗前血清TgAb水平高及合并颈侧区淋巴结转移是患者预后差的独立影响因素,而年长组肿瘤腺外侵犯以及131I治疗前血清TgAb越高患者预后越差,131I治疗后1年内TgAb的变化率可能可以作为预测TgAb阳性患者疾病状态的早期标志物。 展开更多
关键词 分化型甲状腺癌 甲状腺球蛋白抗体 年龄 预后
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部